Overview of the Class Action Lawsuit Against Applied Therapeutics
Levi & Korsinsky, LLP has alerted investors about an emerging class action securities lawsuit involving Applied Therapeutics, Inc. (NASDAQ: APLT). The lawsuit aims to recover losses for shareholders adversely impacted by alleged securities fraud within a specific timeframe.
Class Definition and Timeframe
The class action seeks to support those who experienced financial losses tied to Applied Therapeutics’ activities from January 3, 2024, to December 2, 2024. This period is critical as it encompasses events leading to significant drops in the company's stock prices.
Recent Developments Leading to Stock Declines
According to recent allegations, on November 27, 2024, Applied Therapeutics disclosed that it received a Complete Response Letter (CRL) concerning its New Drug Application (NDA) for govorestat, its leading drug candidate. This announcement revealed deficiencies in the clinical application, which raised concerns regarding regulatory approval.
The market reacted swiftly, and within a few days, shares plummeted. Starting from a closing price of $10.21 on November 26, 2024, the stock corrected to $8.57 on November 27 and further dropped to $2.03 on November 29. By December 2, it had reached $1.75, marking an over 80% decline in a short span. Such dramatic fluctuations underline the market's sensitivity to news related to company performance and regulatory challenges.
Investor Actions and Timeline
For shareholders who believe they have suffered losses during the outlined period, it is vital to act quickly. Investors have until February 18, 2025, to formally request the court to appoint them as lead plaintiff. Engaging in this process allows for potential inclusion in any reparative measures, without the obligation of being the lead plaintiff to share in any financial recovery.
Minimal Costs for Participation
One notable aspect of this lawsuit is that class members may be eligible for compensation without incurring any out-of-pocket expenses. There are no financial obligations associated with participating in this class action—making it accessible for affected investors.
The Expertise of Levi & Korsinsky
Levi & Korsinsky boasts a rich history of over 20 years in successfully championing the rights of shareholders, securing substantial financial reparations in the process. The firm has demonstrated expertise in handling complex securities litigation and is backed by a robust team dedicated to prioritizing clients' interests.
Ranking consistently in ISS Securities Class Action Services' Top 50 Report, Levi & Korsinsky stands out among the top firms in securities litigation within the United States. Their extensive experience equips them to effectively navigate the evolving landscape of securities laws and shareholder rights.
Contact Information
For any inquiries or assistance, interested parties can reach out to Levi & Korsinsky:
Joseph E. Levi, Esq.
Tel: (212) 363-7500
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Frequently Asked Questions
What is a class action lawsuit?
A class action lawsuit allows a group of individuals with similar grievances against a company to sue jointly.
Who can participate in the Applied Therapeutics lawsuit?
Investors who experienced financial losses within the specified timeframe are eligible to participate in the class action.
How can I become a lead plaintiff?
To become a lead plaintiff, you must submit a request to the court by the deadline of February 18, 2025.
Are there any costs involved in joining this lawsuit?
No, there are no costs or fees for class members wishing to participate in the lawsuit.
What should I do if I have questions about my investment?
You can contact Levi & Korsinsky for guidance and support regarding your investment and the legal proceedings.
